List view / Grid view
27 September 2016 | By Niamh Louise Marriott, Digital Content Producer
One example is the development of in vitro assays to enable the testing of 100 or so compounds per month for potential endocrine disrupting effects...
20 September 2016 | By Niamh Louise Marriott, Digital Content Producer
The net proceeds of the proposed placing and subscription shares would be used to fund safety trials for the US development...
16 September 2016 | By Niamh Louise Marriott, Digital Content Producer
Inhibition of the protein kinase CK2 results in a blockade of exactly those signal pathways required by TH17 cells in order to evolve...
8 September 2016 | By Niamh Louise Marriott, Digital Content Producer
Compound kushen injection (CKI) has been used for years in Chinese clinics as an adjunct to western chemotherapy. Researchers used next generation...
25 July 2016 | By Niamh Louise Marriott, Digital Content Producer
Prokarium announced the award of funding from the UK governments for the development of three new vaccines against Zika, bacterial diarrhoea and plague...
24 June 2016 | By Victoria White, Digital Content Producer
The BioIndustry Association and EFPIA have reacted to the news that Britain has voted to leave the European Union (EU)...
20 June 2016 | By Caroline Richards, Editor, Drug Target Review
As Britons go to polling stations to vote in the EU Referendum, we can't help but wonder how you feel...
2 March 2016 | By Victoria White
The US Patent 9,273,283 is the second patent of Celyad allogeneic intellectual property portfolio that is awarded by the USPTO...
Health and Safety Law rarely arouses interest, either amongst companies or lawyers, yet its importance is growing and it has become the area in which companies and their directors are likely to find themselves in the dock, facing a criminal prosecution.
A 2010 overview article on companion diagnostics, compiled by authors Stephen Naylor and Toby Cole, commented on the need for the companion diagnostic to fit into the logistics of the testing laboratory. The intervening five years have shown that patients are demanding more rapid and more convenient testing for diagnosis,…
All new drugs rely, to a greater or lesser extent, on pre-existing research and development. Much of this pre-existing research will have resulted in patented methods and products. A major challenge for all researchers is therefore to develop new drugs which do not infringe other company’s patents.
11 May 2015 | By Victoria White
US and EU Patent Offices have granted Domainex patents for the first generation of inhibitor compounds in its lead programme targeting IKK epsilon and TBK1.
8 April 2015 | By Victoria White
Cardio3 has received a Notice of Allowance from the USPTO for a patent application covering TCR-deficient T-Cells which are engineered to express a CAR...
18 March 2015 | By Victoria White
TxCell SA has announced that a key patent, covering its lead product Ovasave(R) in IBD, is to be granted in the US on 31 March 2015...
11 February 2015 | By Cancer-Code Corporation
Another foundation patent in the burgeoning field of bioelectronic medicine, specifically for treating cancer patients...
